Kevin Shannon

This study designs Ras isoform-specific binders using deep learning to target the C-termini of Ras proteins, enabling specific inhibition and study of their roles in biology and disease.

This study shows that AML relapse after BET inhibitor or chemotherapy involves Myc-Ras transcriptional changes, highlighting transcriptional plasticity in relapsed leukemias.

This study shows TP53 mutations cause resistance to revumenib in AML and suggests combining MCL-1 inhibitors with menin inhibitors could be effective.

This study validates the palmitoylation cycle as a therapeutic target in NRAS-mutant cancers by showing that inhibiting ABHD17 reduces tumor growth and synergizes with MEK inhibitors.